Back to News
Market Impact: 0.15
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
Source: PR Newswire
Healthcare & BiotechTechnology & InnovationProduct Launches
SiBionics presented its "See More, Act Earlier" diabetes-care vision at EASD 2026, focused on continuous sensing and capabilities beyond glucose monitoring. The announcement signals product and technology positioning in diabetes management, but provides no financial metrics, regulatory milestones, clinical data, or commercialization timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- SoftBank’s Masayoshi Son Has Rare Cautionary Note on AI Safety
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- Germany's Merz arrives in Kyiv to finalize drone deal, release aid
- Russia hits Kyiv bridge as Germany’s Merz visits Ukraine’s capital
- Germany’s Merz arrives in Kyiv to the sound of sirens and explosions
- Schneider Electric close to $20 bln deal of U.S. software maker PTC - report